What the FDA labels say about taking them together
Dabigatran and sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names dabigatran in its drug interactions section; the dabigatran labels PlainMeds reads (2) do not name sofosbuvir/velpatasvir/voxilaprevir. The sofosbuvir/velpatasvir/voxilaprevir label: “Clinical monitoring of dabigatran is recommended when coadministered with VOSEVI. Refer to dabigatran etexilate prescribing information for dose modification recommendations in the setting of moderate renal impairment.”
Check it at the source: the dabigatran FDA label on DailyMed (effective June 25, 2025, Boehringer Ingelheim Pharmaceuticals Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the dabigatran label say about sofosbuvir/velpatasvir/voxilaprevir?
Dabigatran's label (effective June 25, 2025) and its 1 other brand-application label do not name sofosbuvir/velpatasvir/voxilaprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pradaxa), Boehringer Ingelheim Pharmaceuticals Inc., effective June 25, 2025 (SPL set ba74e3cd-b06f-4145-b284-5fd6b84ff3c9), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about dabigatran?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: dabigatran etexilate; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ dabigatran; Clinical Effect/Recommendation: Clinical monitoring of dabigatran is recommended when coadministered with VOSEVI. Refer to dabigatran etexilate prescribing information for dose modification recommendations in the setting of moderate renal impairment.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dabigatran | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.795 per capsule 150 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once